Evidence map›Paper›PMID 42646366›Full record

ReviewNeurology international2026

Pridopidine Mediated Sigma-1 Receptor Activation and Therapeutic Implications in Neurodegenerative Diseases.

Ahmed I Anwar, Abdul-Rahman A Hegazi, Hamsa Priya Bhuchakra, Joshua R Nelson, Ty L Birdsong, Cy J Fontenot, Majed Zeibo, Moiz M Fazal-Ur-Rehman, Harrison P Bieber, Claudia J Spring and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ahmed I AnwarSchool of Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0002-3140-357X
Abdul-Rahman A HegaziDepartment of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.ORCID 0009-0009-5463-7481
Hamsa Priya BhuchakraDepartment of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0003-0772-5015
Joshua R NelsonSchool of Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.ORCID 0009-0008-2568-2964
Ty L BirdsongSchool of Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Cy J FontenotSchool of Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Majed ZeiboSchool of Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Moiz M Fazal-Ur-RehmanSchool of Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Harrison P BieberSchool of Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.ORCID 0009-0003-4061-7865
Claudia J SpringSchool of Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Joshua L SmithSchool of Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Ibraheem A HachemSchool of Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.ORCID 0009-0001-6746-4008
Taranjit SinghSchool of Medicine, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
M Farris SawayaDepartment of Pharmacology, Toxicology & Neuroscience, School of Graduate Studies, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.
Kevin S MurnaneDepartment of Pharmacology, Toxicology & Neuroscience, School of Graduate Studies, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0002-8143-0541
Alan D KayeDepartment of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USA.ORCID 0000-0003-2464-0187

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases are targets for pridopidine therapy, which aims to improve quality of life through neuroprotective mechanisms that involve sigma-1 receptor (S1R) activation. Neurodegenerative motor and cognitive diseases are influenced by dopamine imbalance, where disruptions in pathways contribute to states that are hyperkinetic or hypokinetic, while current dopaminergic treatments are symptomatic rather than disease-modifying, especially for Huntington's disease and Amyotrophic lateral sclerosis. This review summarizes the mechanisms underlying pridopidine-mediated neuroprotection and examines the current evidence supporting its therapeutic potential. The S1R is an endoplasmic reticulum-mitochondria-associated chaperone involved in homeostasis of calcium, stress regulation, and mitochondrial function. Pridopidine is a small lipophilic molecule that crosses the blood-brain barrier and acts as an S1R agonist, with minimal dopamine D2 receptor occupancy. Activation of S1R by pridopidine modulates calcium signaling and enhances anti-apoptotic activity. Collectively, available evidence suggests that pridopidine may improve motor outcomes and slow disease progression in Huntington's disease and amyotrophic lateral sclerosis, supporting its promise as a disease-modifying therapeutic strategy.

Indexed as

amyotrophic lateral sclerosisHuntington’s diseaseneurodegenerationpridopidineS1Rsigma-1-receptor

Identifiers

PMID42646366
PMCPMC13516327

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.